Hs Troponin I Test: An Evidence-Based Cardiac Biomarker Predicts Future Cardiac Events

India records one of the highest burdens of cardiovascular disease (CVD) worldwide. The annual number of deaths from CVD in India is projected to rise from 2.26 million (1990) to 4.77 million (2020). 

In recent time, heart attacks and other cardiovascular disorders are most common in younger people. A sedentary lifestyle, physical inactivity, unhealthy diet, excessive alcohol consumption, smoking, high blood pressure, Diabetes, and high cholesterol are the most common behavioral risk factors for heart disease and stroke. These "risk factors" indicate a higher chance of complications including heart failure, stroke, and other disorders.

Thus, it becomes important to identify your risk factors and detect the cardiovascular disease as early as possible so that the condition can be managed and adverse outcomes can be prevented with early Actions. 

Troponin I is the only troponin isotope present in the myocardium. Within hours of the development of symptoms of myocardial infarction or ischemia injury, troponin I is released into the bloodstream. It can be identified three to six hours after the onset of chest discomfort, reaches its peak concentrations between twelve and sixteen hours later, and stays elevated for five to nine days.

Dr. B. Lal Clinical Laboratory introduced Hs Troponin I Test (Heart Secure Test) i.e., High Sensitive Troponin I, a quantitative determination of cardiac troponin I in human plasma and serum in apparently healthy individuals. hs Troponin I, highly cardiac specific and sensitive biomarker that detects cardiac injury from any cause and more precisely predict risk stratification (low/moderate/high risk) to help identify the extent of risk for future cardiac events in asymptomatic and healthy individuals, prioritizing care of those who are at higher risk to be given special treatment to help prevent severe consequences.

Also, read: How to Save Tax with Suraksha Health Checkup Packages Under Section 80D

With reference to the diagnostic findings, it aids the categorization of asymptomatic individuals at risk of CVD, including cardiovascular death, Myocardial Infarction, coronary revascularization, heart failure (HF), or ischaemic stroke as well as to aid in the assessment of 30-day and 90-day prognosis relative to all-cause mortality and major adverse cardiac events consisting of Myocardial Infarction, revascularization, and cardiac death in patients who show Acute coronary syndrome symptoms (ACS).

The most common signs of a heart attack include significant chest pain, rapid heartbeat, shortness of breath, nausea, vomiting, dizziness, and perspiration. However, additional symptoms include chest pain/discomfort in the chest, shoulder, neck, arm, jaw, or back pain, pressure, heaviness, or tightness. 

According to Dr. Utkarsh Sharma, MD Pathology, Dr. B. Lal Clinical Lab. “In the post-Covid era, we have undoubtedly witnessed increased incidences of sudden cardiac death and other cardiovascular morbidities. Adding to this, a sedentary lifestyle, poor eating habits, stress, and lack of exercise are other factors that we all know contribute to cardiovascular morbidity. With evidence supporting that hsTropI is an extremely useful predictive marker in order to stratify risk of future cardiovascular events in apparently asymptomatic individuals, we are hopeful that judicious use of this test can help people at risk by strongly motivating them to adopt the necessary lifestyle changes and other measures to negotiate the risk.” 

Predict the future Heart Risks with our Heart Secure Test Now!!